PL2481405T3 - Przeciwrakowe nanocząstki paklitakselu i albuminy w kombinacji z bewacyzumabem - Google Patents

Przeciwrakowe nanocząstki paklitakselu i albuminy w kombinacji z bewacyzumabem

Info

Publication number: PL2481405T3
Authority: PL; Poland
Prior art keywords: paclitaxel; nanoparticles; albumin; combination; against cancer
Prior art date: 2006-11-06

Application number

PL12154995.0T

Other languages

English (en)

Polish (pl)

Inventor

Neil P. Desai

Patrick Soon-Shiong

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-06

Filing date

2007-11-06

Publication date

2016-09-30

2007-11-06 Application filed filed Critical

2016-09-30 Publication of PL2481405T3 publication Critical patent/PL2481405T3/pl

Links

102000009027 Albumins Human genes 0.000 title 1
108010088751 Albumins Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
229930012538 Paclitaxel Natural products 0.000 title 1
229960000397 bevacizumab Drugs 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000002105 nanoparticle Substances 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Nanotechnology (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL12154995.0T 2006-11-06 2007-11-06 Przeciwrakowe nanocząstki paklitakselu i albuminy w kombinacji z bewacyzumabem PL2481405T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11/594,417 US20070166388A1 (en)	2005-02-18	2006-11-06	Combinations and modes of administration of therapeutic agents and combination therapy

Publications (1)

Publication Number	Publication Date
PL2481405T3 true PL2481405T3 (pl)	2016-09-30

Family

ID=39111840

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL12154995.0T PL2481405T3 (pl)	2006-11-06	2007-11-06	Przeciwrakowe nanocząstki paklitakselu i albuminy w kombinacji z bewacyzumabem
PL07839976T PL2097078T3 (pl)	2006-11-06	2007-11-06	Przeciwrakowe nanocząsteczki paklitakselu i albuminy w kombinacji z bewacyzumabem

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL07839976T PL2097078T3 (pl)	2006-11-06	2007-11-06	Przeciwrakowe nanocząsteczki paklitakselu i albuminy w kombinacji z bewacyzumabem

Country Status (22)

Country	Link
US (1)	US20070166388A1 (2)
EP (3)	EP2097078B1 (2)
JP (3)	JP5931323B2 (2)
KR (4)	KR20180012339A (2)
CN (2)	CN101573108A (2)
AU (1)	AU2007317859B2 (2)
BR (1)	BRPI0718528A2 (2)
CA (1)	CA2668607A1 (2)
CY (2)	CY1115271T1 (2)
DK (2)	DK2481405T3 (2)
ES (2)	ES2469716T3 (2)
HU (1)	HUE028472T2 (2)
IL (2)	IL198576A (2)
MX (1)	MX2009004803A (2)
NO (1)	NO343908B1 (2)
NZ (1)	NZ576856A (2)
PL (2)	PL2481405T3 (2)
PT (2)	PT2097078E (2)
RU (2)	RU2009121568A (2)
SI (2)	SI2481405T1 (2)
WO (1)	WO2008057562A1 (2)
ZA (1)	ZA200903132B (2)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030133955A1 (en) *	1993-02-22	2003-07-17	American Bioscience, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US20070117862A1 (en) *	1993-02-22	2007-05-24	Desai Neil P	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070092563A1 (en) *	1996-10-01	2007-04-26	Abraxis Bioscience, Inc.	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
BRPI9810945B8 (pt) *	1997-06-27	2021-05-25	Abraxis Bioscience Inc	formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
US8853260B2 (en) *	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
CN103405405A (zh) *	2002-12-09	2013-11-27	阿布拉西斯生物科学有限责任公司	组合物和传递药剂的方法
US8735394B2 (en) *	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl)	2005-02-18	2012-01-31	Abraxis Bioscience Llc	Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
AU2006284657B2 (en) *	2005-08-31	2012-07-19	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR101420445B1 (ko) *	2005-08-31	2014-07-16	아브락시스 바이오사이언스, 엘엘씨	수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
JP5590882B2 (ja) *	2006-06-26	2014-09-17	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ）
US20080280987A1 (en) *	2006-08-31	2008-11-13	Desai Neil P	Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
JP2010508277A (ja) *	2006-11-01	2010-03-18	ジョージメイソンインテレクチュアルプロパティーズ，インコーポレイテッドオブフェアファックス，バージニア	癌を検出および抑制するための方法
EP3470071A1 (en)	2006-12-14	2019-04-17	Abraxis BioScience, LLC	Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008109163A1 (en) *	2007-03-07	2008-09-12	Abraxis Bioscience, Llc.	Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en) *	2007-05-03	2010-07-01	Desai Neil P	Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) *	2007-06-01	2014-08-27	アブラクシスバイオサイエンス，エルエルシー	再発性癌の処置のための方法および組成物
CA2686225A1 (en) *	2007-06-22	2008-12-31	Scidose Llc	Solubilized formulation of docetaxel without tween 80
ITMI20080284A1 (it) *	2008-02-22	2009-08-23	Indena Spa	Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
MX2010011165A (es) *	2008-04-10	2011-02-22	Abraxis Bioscience Llc	Composiciones de derivados de taxano hidrofobos y sus usos.
WO2010003057A2 (en)	2008-07-03	2010-01-07	Mayo Foundation For Medical Education And Research	Treating cancer
EP2153821A1 (en) *	2008-08-06	2010-02-17	BioAlliance Pharma	Oral formulations of camptothecin derivatives
SG172997A1 (en) *	2009-01-16	2011-08-29	Rigel Pharmaceuticals Inc	Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
CN102427728A (zh) *	2009-03-13	2012-04-25	阿布拉科斯生物科学有限公司	用硫代秋水仙碱衍生物进行联合治疗
HRP20192259T1 (hr)	2009-04-15	2020-03-06	Abraxis Bioscience, Llc	Pripravci nanočestica bez priona i metode njihove proizvodnje
JP2012532879A (ja) *	2009-07-07	2012-12-20	ノームオキシーズ，インコーポレイテッド	イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
US8912228B2 (en)	2009-10-19	2014-12-16	Scidose Llc	Docetaxel formulations with lipoic acid
US8541465B2 (en) *	2009-10-19	2013-09-24	Scidose, Llc	Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) *	2009-10-19	2011-04-21	Scidose Llc	Solubilized formulation of docetaxel
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
KR102104197B1 (ko) *	2010-02-23	2020-04-24	제넨테크, 인크.	난소암의 치료를 위한 항혈관신생 요법
CA3051495A1 (en)	2010-03-26	2011-09-29	Abraxis Bioscience, Llc	Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR20130028727A (ko) *	2010-03-29	2013-03-19	아브락시스 바이오사이언스, 엘엘씨	치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en)	2010-03-29	2017-12-22	Abraxis Bioscience Llc	Methods of treating cancer
BR112012030909A2 (pt)	2010-06-04	2020-08-18	Abraxis Bioscience, Llc	métodos de tratamento de câncer pancreático
WO2011156119A1 (en) *	2010-06-07	2011-12-15	Abraxis Bioscience, Llc	Combination therapy methods for treating proliferative diseases
US20120121510A1 (en) *	2010-11-11	2012-05-17	Brem Rachel F	Localized therapy following breast cancer surgery
WO2012068098A1 (en) *	2010-11-15	2012-05-24	Oncomed Pharmaceuticals, Inc.	Methods for treating cancer with dll4 antagonists
PT2707030T (pt)	2011-05-09	2020-05-22	Mayo Found Medical Education & Res	Tratamentos de cancro
US9125884B2 (en)	2011-11-01	2015-09-08	Celgene Corporation	Methods for treating cancers using oral formulations of cytidine analogs
WO2013085902A1 (en)	2011-12-05	2013-06-13	The University Of Texas M.D.	Combination therapy methods for treating an inflammatory breast cancer
JP6216721B2 (ja)	2011-12-14	2017-10-18	アブラクシスバイオサイエンス，エルエルシー	粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
WO2013135602A2 (en)	2012-03-13	2013-09-19	F. Hoffmann-La Roche Ag	Combination therapy for the treatment of ovarian cancer
US10413606B2 (en)	2012-10-01	2019-09-17	Mayo Foundation For Medical Education And Research	Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
EP2953622B1 (en) *	2013-02-11	2021-03-24	Abraxis BioScience, LLC	Methods of treating melanoma
EP3698784A1 (en)	2013-03-12	2020-08-26	Abraxis BioScience, LLC	Methods of treating lung cancer
EP2968191B1 (en)	2013-03-14	2021-06-16	Abraxis BioScience, LLC	Methods of treating bladder cancer
US10842969B2 (en)	2013-10-25	2020-11-24	Mercator Medsystems, Inc.	Systems and methods of treating malacia by local delivery of hydrogel to augment tissue
WO2015134543A1 (en) *	2014-03-05	2015-09-11	Sorrento Therapeutics, Inc.	Pharmacokinetically equivalent nanoparticle compositions
EP2924022A1 (en) *	2014-03-27	2015-09-30	INDENA S.p.A.	Amorphous form of a thiocolchicine derivative
US20160250351A1 (en)	2014-06-13	2016-09-01	Mayo Foundation For Medical Education And Research	Treating Lymphomas
EP3834889A1 (en)	2014-06-16	2021-06-16	Mayo Foundation for Medical Education and Research	Treating myelomas
WO2015195634A1 (en)	2014-06-17	2015-12-23	Celgne Corporation	Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
CN104434808A (zh) *	2014-07-03	2015-03-25	石药集团中奇制药技术（石家庄）有限公司	一种治疗性纳米粒子及其制备方法
DK3204413T3 (da) *	2014-10-06	2019-12-09	Mayo Found Medical Education & Res	Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
US10527604B1 (en)	2015-03-05	2020-01-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en)	2015-03-05	2020-07-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
PL3998069T3 (pl)	2015-06-29	2025-03-31	Abraxis Bioscience, Llc	Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
JP6921802B2 (ja) *	2015-08-18	2021-08-18	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	キャリア結合剤組成物およびそれを作製および使用する方法
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
WO2017176265A1 (en) *	2016-04-06	2017-10-12	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
CN105288639A (zh) *	2015-11-23	2016-02-03	中国药科大学	一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用
WO2017120501A1 (en)	2016-01-07	2017-07-13	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon
WO2017139698A1 (en)	2016-02-12	2017-08-17	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
US11305020B2 (en)	2016-03-21	2022-04-19	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en)	2016-03-21	2019-11-20	Mayo Foundation for Medical Education and Research	PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
AU2017307618A1 (en) *	2016-08-05	2019-02-21	Mayo Foundation For Medical Education And Research	Modified antibody-albumin nanoparticle complexes for cancer treatment
WO2018038253A1 (ja) *	2016-08-26	2018-03-01	哲治奥野	微小ナノ化薬剤およびその利用
CA3035377A1 (en)	2016-09-01	2018-03-08	Mayo Foundation For Medical Education And Research	Nanoparticle compositions for targeting t-cell cancers
CN109890419A (zh)	2016-09-01	2019-06-14	梅约医学教育与研究基金会	用于治疗癌症的载体-pd-l1结合剂组合物
EP3509643A1 (en) *	2016-09-06	2019-07-17	Mayo Foundation for Medical Education and Research	Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2018048816A1 (en)	2016-09-06	2018-03-15	Mayo Foundation For Medical Education And Research	Methods of treating pd-l1 expressing cancer
CN106310291A (zh) *	2016-09-14	2017-01-11	东南大学	主动靶向抗肿瘤纳米药物及其制备方法和应用
KR102528406B1 (ko)	2016-10-27	2023-05-03	셀젠 콴티셀 리서치, 인크.	브로모도메인 및 엑스트라-말단 단백질 억제제 병용 치료요법
AU2017350957B2 (en) *	2016-10-28	2020-10-29	Nant Holdings Ip, Llc	Avatar dendritic cells: the neoantigen natural killer T-cell chemo immuno radiation composition inducing immunogenic cell death
RU2020118594A (ru)	2017-11-06	2021-12-09	Рапт Терапьютикс, Инк.	Противораковые агенты
WO2019104042A1 (en) *	2017-11-21	2019-05-31	University Of Iowa Research Foundation	Synthetically lethal nanoparticles for treatment of cancers
EA202091514A1 (ru) *	2017-12-19	2020-09-15	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
FI3743091T3 (fi)	2018-01-26	2025-01-03	Univ California	Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
IL277402B1 (en)	2018-03-20	2026-04-01	Abraxis Bioscience Llc	Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
JP7832108B2 (ja)	2019-10-28	2026-03-17	アブラクシスバイオサイエンス，エルエルシー	アルブミンおよびラパマイシンの医薬組成物
WO2021108255A1 (en)	2019-11-25	2021-06-03	The Regents Of The University Of California	Long-acting vegf inhibitors for intraocular neovascularization
KR102263606B1 (ko)	2020-02-11	2021-06-10	충북대학교 산학협력단	파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5470571A (en)	1988-01-27	1995-11-28	The Wistar Institute	Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL98528A0 (en)	1990-06-21	1992-07-15	Merck & Co Inc	Pharmaceutical compositions containing hybrid for killing bladder cancer cells
EP0531472B1 (en)	1991-03-06	2003-08-13	MERCK PATENT GmbH	Humanized monoclonal antibodies
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
WO1995019171A1 (en)	1994-01-14	1995-07-20	Cell Therapeutics, Inc.	Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
JP3957765B2 (ja)	1997-04-07	2007-08-15	ジェネンテク・インコーポレイテッド	抗ｖｅｇｆ抗体
HUP0102048A3 (en)	1998-04-16	2002-12-28	Eurovita As	Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga and their use
CA2369740A1 (en)	1999-04-22	2000-11-02	American Biosciences, Inc.	Long term administration of pharmacologically active agents
ITMI20001107A1 (it) *	2000-05-18	2001-11-18	Acs Dobfar Spa	Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040143004A1 (en)	2002-02-26	2004-07-22	Joseph Fargnoli	Metronomic dosing of taxanes
CN103405405A (zh)	2002-12-09	2013-11-27	阿布拉西斯生物科学有限责任公司	组合物和传递药剂的方法
MXPA05012723A (es) *	2003-05-30	2006-02-08	Genentech Inc	Tratamiento con anticuerpos anti-vgf.
AR046510A1 (es) *	2003-07-25	2005-12-14	Regeneron Pharma	Composicion de un antagonista de vegf y un agente anti-proliferativo
BRPI0414698A (pt) *	2003-09-23	2006-11-28	Novartis Ag	combinação de um inibidor receptor de vegf com um agente quimioterapêutico
WO2006001911A2 (en)	2004-05-06	2006-01-05	Genentech, Inc.	Crystal structure of the hepatocyte growth factor beta chain and methods of use
KR20120064120A (ko)	2004-06-01	2012-06-18	제넨테크, 인크.	항체 약물 접합체 및 방법
TW201422238A (zh)	2004-06-04	2014-06-16	Genentech Inc	Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
SV2006002143A (es)	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US8772269B2 (en) *	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP5475234B2 (ja) *	2005-01-21	2014-04-16	アステックス・セラピューティクス・リミテッド	医薬化合物
SI1853250T1 (sl)	2005-02-18	2012-01-31	Abraxis Bioscience Llc	Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
JPWO2006090928A1 (ja) *	2005-02-28	2008-07-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	スルホンアミド化合物の血管新生阻害物質との新規併用
AU2006284657B2 (en) *	2005-08-31	2012-07-19	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR101420445B1 (ko) *	2005-08-31	2014-07-16	아브락시스 바이오사이언스, 엘엘씨	수 난용성 제약학적 약제 및 항균제를 포함하는 조성물

2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
2007
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/en active
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown

Also Published As

Publication number	Publication date
NZ576856A (en)	2012-06-29
KR20180012339A (ko)	2018-02-05
PT2481405E (pt)	2016-06-08
MX2009004803A (es)	2009-07-09
IL198576A0 (en)	2010-02-17
KR20150065957A (ko)	2015-06-15
PL2097078T3 (pl)	2014-09-30
RU2009121568A (ru)	2010-12-20
AU2007317859B2 (en)	2013-07-25
SI2097078T1 (sl)	2014-07-31
CA2668607A1 (en)	2008-05-15
RU2013149282A (ru)	2015-05-10
IL244390A (en)	2017-04-30
KR20090087906A (ko)	2009-08-18
KR20170016017A (ko)	2017-02-10
PT2097078E (pt)	2014-07-25
WO2008057562A1 (en)	2008-05-15
HK1173976A1 (en)	2013-05-31
ES2469716T3 (es)	2014-06-18
JP2014043454A (ja)	2014-03-13
JP2010509331A (ja)	2010-03-25
US20070166388A1 (en)	2007-07-19
EP3108885A1 (en)	2016-12-28
EP2097078A1 (en)	2009-09-09
SI2481405T1 (sl)	2016-08-31
EP2481405A1 (en)	2012-08-01
HUE028472T2 (en)	2016-12-28
IL244390A0 (en)	2016-04-21
DK2481405T3 (en)	2016-06-06
KR101857142B1 (ko)	2018-05-14
JP5931323B2 (ja)	2016-06-08
EP2481405B1 (en)	2016-03-23
DK2097078T3 (da)	2014-05-12
EP2097078B1 (en)	2014-04-16
AU2007317859A1 (en)	2008-05-15
JP2016014073A (ja)	2016-01-28
NO20092179L (no)	2009-08-06
CN104940929A (zh)	2015-09-30
CN101573108A (zh)	2009-11-04
ES2576289T3 (es)	2016-07-06
ZA200903132B (en)	2010-08-25
NO343908B1 (no)	2019-07-01
CY1115271T1 (el)	2017-01-04
IL198576A (en)	2016-12-29
RU2673805C2 (ru)	2018-11-30
BRPI0718528A2 (pt)	2013-11-19
CY1117725T1 (el)	2017-05-17

Publication	Publication Date	Title
IL244390A0 (en)	2016-04-21	Nonparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HRP20181217T1 (hr)	2018-10-05	Nanočestica koja kao antikancerogeno sredstvo sadrži rapamicin i albumin
EP2038041A4 (en)	2010-02-17	THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
IL247617A0 (en)	2016-11-30	Peptide nanoparticles and their uses
IL199609A0 (en)	2010-05-17	Antifolate agent combinations in the treatment of cancer
EP2048189A4 (en)	2009-09-30	ALUMINUM OXIDE NANOPARTICLE WITH COATED SURFACE AND RESIN COMPOSITION THEREOF
IL208591A0 (en)	2010-12-30	Nanoparticle formulations and uses thereof
PL2012872T3 (pl)	2020-12-28	Leczenia nowotworu z użyciem pól elektromagnetycznych w połączeniu z lekami przeciwnowotworowymi
ZA200902161B (en)	2010-06-30	Antiobodies and immunoconjugates and uses therefor
GB2461473B (en)	2012-10-24	Nanoparticles and fabrication thereof
IL209361A0 (en)	2011-01-31	Combination therapy with pm00104 and another antitumor agent
IL242077B (en)	2019-10-31	Sp–1 complexes with nanoparticles and their use
GB0503216D0 (en)	2005-03-23	Nanoparticles and uses there of
GB0603433D0 (en)	2006-04-05	Nanoparticle and nanocomposite films
HK1156219A (en)	2012-06-08	Combination therapy with pm00104 and another antitumor agent